For Bayer, a Supreme Court Ruling Is the Only Catalyst That Matters
Published on 06/18/2026 at 12:44 | Redaktion boerse-global.de
Bayer’s stock jumped 4.6% to €37.51 on Thursday, hitting a monthly high as investors placed a high-stakes bet on the US Supreme Court. At issue in the case of Monsanto v. Durnell is whether federal pesticide regulation by the EPA preempts state-level warning obligations. A ruling in the German conglomerate’s favour would effectively neuter the vast majority of the roughly 65,000 outstanding glyphosate lawsuits, wiping away a liability that has weighed on the balance sheet since the Monsanto acquisition. More than 100,000 claims have been filed in total, and Bayer has already spent over $10bn on settlements. The decision, expected as early as June, offers a binary upside that no quarterly earnings can match.
Yet beneath the legal drama, the operating business is quietly delivering. Bayer beat consensus expectations in the first quarter of 2026, posting adjusted EBITDA of €4.45bn — up 9% year-on-year and well ahead of the €3.93bn analysts had pencilled in. Management is guiding for full-year revenue of €44.5bn to €46.5bn. Barclays calls 2026 the trough, forecasting a return to mid-single-digit top-line growth from 2027 and setting a €48 price target. UBS is even more bullish at €52. With the stock at €37.51, the average analyst target of roughly €49 implies nearly 30% upside — if the legal overhang lifts.
The catalyst pool runs beyond the courtroom. Brussels recently ruled that foods produced with modern gene-editing techniques can be sold in the EU without special labelling, a structural boost for Bayer’s Crop Science division. The move adds a layer of fundamental support that was absent earlier in the year, when the stock was still struggling to shake off the Monsanto legacy.
Should investors sell immediately? Or is it worth buying Bayer?
Of the eleven analysts covering Bayer, eight rate the shares a Buy and three a Hold. The consensus is that operational momentum is building, but the share price will remain tethered to judicial developments. A Supreme Court win would unlock a re-rating that the current €37.51 level — barely changed on the year — has long denied.
For now, Bayer is the clearest example of a binary trade in the European pharmaceutical space. The stock’s Thursday rally lifted it to the top of the DAX, leaving peers like SAP and Vonovia in the dust as macro headwinds hit those sectors. But the same legal trigger that propelled the shares higher could just as easily reverse the gains if the Court rules against the company. Every percentage point of movement in the coming weeks will reflect a single question: will the justices end the glyphosate saga, or let it drag on?
Ad
Bayer Stock: New Analysis - 18 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
